



OPEN


# Individual Calculation of Effective Dose and Risk of Malignancy Based on Monte Carlo Simulations after Whole Body Computed Tomography

Markus Kopp<sup>1</sup>✉, Tobias Loewe<sup>2</sup>, Wolfgang Wuest<sup>1</sup>, Michael Brand<sup>1</sup>, Matthias Wetzl<sup>1</sup>, Wolfram Nitsch<sup>1</sup>, Daniela Schmidt<sup>3</sup>, Michael Beck<sup>3</sup>, Bernhard Schmidt<sup>4</sup>, Michael Uder<sup>1</sup> & Matthias May<sup>1</sup>

Detailed knowledge about radiation exposure is crucial for radiology professionals. The conventional calculation of effective dose (ED) for computed tomography (CT) is based on dose length product (DLP) and population-based conversion factors (k). This is often imprecise and unable to consider individual patient characteristics. We sought to provide more precise and individual radiation exposure calculation using image based Monte Carlo simulations (MC) in a heterogeneous patient collective and to compare it to phantom based MC provided from the National Cancer Institute (NCI) as academic reference. Dose distributions were simulated for 22 patients after whole-body CT during Positron Emission Tomography-CT. Based on MC we calculated individual Lifetime Attributable Risk (LAR) and Excess Relative Risk (ERR) of cancer mortality.  $ED_{MC}$  was compared to  $ED_{DLP}$  and  $ED_{NCI}$ .  $ED_{DLP}$  ( $13.2 \pm 4.5$  mSv) was higher compared to  $ED_{NCI}$  ( $9.8 \pm 2.1$  mSv) and  $ED_{MC}$  ( $11.6 \pm 1.5$  mSv). Relative individual differences were up to  $-48\%$  for  $ED_{MC}$  and  $-44\%$  for  $ED_{NCI}$  compared to  $ED_{DLP}$ . Matching pair analysis illustrates that young age and gender are affecting LAR and ERR significantly. Because of these uncertainties in radiation dose assessment automated individual dose and risk estimation would be desirable for dose monitoring in the future.

The Euratom council directive (2013/59/Euratom) emphasizes the need for patient radiation dose monitoring in clinical routine<sup>1</sup>. Computed tomography (CT) is indispensable for contemporary patient care, but many studies suggest a relation between low dose protracted radiation exposure and an increased incidence of malignancy based on the linear Non-threshold Dose-Response Model<sup>2</sup>. Therefore, detailed knowledge of radiation exposure from CT examinations is crucial for radiology healthcare professionals in clinical routine to detect and address increased risks of malignancy. Widely used parameters for radiation exposure assessment like the volumetric CT dose index ( $CTDI_{vol}$ ) and the Dose Length Product (DLP) characterize scanner radiation output, but are unable to take individual patient characteristics into account<sup>3</sup>. Conversion to effective dose ( $ED_{DLP}$ ) is feasible using population-based conversion factors (k) that take the averaged radiosensitivity in defined anatomic regions into account<sup>4</sup>. A variety of different k-factors are recommended in the literature for different volumes (e.g. head, thorax, abdomen, pelvis) and different CT-scanners<sup>5,6</sup>. These k-factors are mostly derived from phantom models that try to represent average patient anatomy in western populations, but are unable to respect individual anatomy like missing organs due to aplasia or resection, organ hypo- or hypertrophy, skeletal deformations and metal implants. Nevertheless, these programs, like e.g. the National Cancer Institute (NCI) dosimetry system for CT, can be considered as current academic reference ( $ED_{NCI}$ )<sup>7</sup>. However, the routinely performed calculation of  $ED_{DLP}$  is imprecise and the degree of difference to the real ED in each individual patient is unknown. Risk estimates that

<sup>1</sup>Department of Radiology, University Hospital Erlangen, Erlangen, Germany. <sup>2</sup>Institute of Medical Microbiology and Hygiene, University of Technology Dresden, Dresden, Germany. <sup>3</sup>Department of Nuclear Medicine, University Hospital Erlangen, Erlangen, Germany. <sup>4</sup>Siemens Healthineers GmbH, Forchheim, Germany. ✉e-mail: [markus.kopp@uk-erlangen.de](mailto:markus.kopp@uk-erlangen.de)



**Figure 1.** Illustration of study design.

are calculated on these imprecise data could then easily be misinterpreted. Therefore, conventionally calculated  $ED_{DLP}$  can be used for comparison between different CT-scanners or different examination protocols, but should not be used for comparison between different patient collectives or for radiation risk estimation<sup>8,9</sup>.

Stochastic estimation of radiation exposure from CT is feasible by Monte Carlo (MC) simulations. Romanyukha *et al.* used computational phantoms and MC-simulations to calculate body size-specific conversion factors from regression curves<sup>10</sup>. Huda *et al.* were able to show that this phantom based technique is also feasible to derive organ doses and to use these for cancer risk estimation<sup>11</sup>. Only few studies with small numbers of mostly pediatric patients used MC simulations for individual dose and risk estimation per patient, probably due to the high computational power needed<sup>12,13</sup>. The main drawback of MC calculations is that they are limited to the reconstructed body volume. Therefore, overexposure in z-axis and scattered radiation to the organs outside the directly exposed volume cannot be taken into account.

Detailed information about biological effects of low-level ionizing radiation is available from the National Academy of Sciences report number seven about *Health Risks from Exposure to Low Levels of Ionizing Radiation* (BEIR VII). The authors of BEIR VII report follow the linear Non-threshold Dose-Response Model and presume that the risk of cancer incidence and mortality due to medical examinations are mainly based on low-level ionizing radiation dose, age and gender<sup>14</sup>.


The aim of this study was to provide individual calculations of ED in whole-body exposure derived from MC calculations ( $ED_{MC}$ ) and to compare them with the conventional method ( $ED_{DLP}$ ) and the academic reference ( $ED_{NCI}$ ) following an equivalence hypothesis in a heterogeneous study collective. Furthermore, cancer risk estimates that are based on  $ED_{MC}$  should allow to evaluate the impact of patient characteristics on individual risk of malignancy. Whole body CT from combined Positron Emission Tomography (PET)-CT examinations were exclusively selected in order to minimize the indeterminate radiation dose to body parts outside the imaging volume that cannot be assessed by MC.

## Methods

**Study design.** Twenty-two patients from a collective of 34 consecutive patients, with clinical indication for whole body PET-CT, were retrospectively included (Fig. 1). Inclusion criteria were the complete and artifact-free coverage of the scan volume, sufficient intra-venous contrast injection and full availability of individual patient data including age, height, weight and body mass index (BMI). Exclusion criteria were severe artifacts ( $n = 0$ ) and examinations without contrast injection ( $n = 12$ ). Clinical indications were infectious diseases ( $n = 8$ ), bronchial carcinoma ( $n = 6$ ), head and neck cancer ( $n = 3$ ), cancer of unknown primary ( $n = 2$ ), malignant melanoma ( $n = 2$ ) and retroperitoneal fibrosis ( $n = 1$ ).

Written informed consent was obtained and archived for each patient. The study was approved by the local ethics committee of the Friedrich-Alexander University Erlangen-Nuremberg and complied with the Declaration of Helsinki.

**Image acquisition.** All examinations were performed with continuous volume acquisition using a Siemens Biograph True Point 64 PET-CT (Siemens Healthcare GmbH, Forchheim, Germany). Indication, supervision and image analysis were performed by senior physicians with extensive experience in PET-CT (>6 years). CT was performed from head to mid-femur by a single spiral acquisition in a cranio-caudal direction using a tube voltage of 120 kV, anatomic tube current modulation with a reference tube-current time product of 170 mAs, pitch 0.8, gantry rotation time 0.5 seconds and  $64 \times 0.6$  mm slice acquisition by  $32 \times 0.6$  mm detector collimation and z-axis flying focal spot double sampling<sup>15</sup>. Unlike in diagnostic CT, where different body parts (e.g.




**Figure 2.** Calculation of effective dose: (A) contrast-enhanced CT acquisition; (B) relative dose distribution from MC simulations; (C) organ segmentation used for organ dose calculation; (D) phantom illustration of the National Cancer Institute dosimetry system for CT.

head/neck and thorax/abdomen) are often examined in multiple contrast phases and different positions, PET-CT uses single spiral acquisitions with only one single bolus injection allowing for complete coverage of all body organs without overlapping of anatomic regions. Therefore, the effect of scattered radiation to all radiosensitive tissues can be taken into account by MC calculations and the effect of overranging in the beginning and end of the spiral acquisition can be neglected<sup>16</sup>. All patients received body weight adapted intravenous injection of <sup>18</sup>F-fluorodeoxyglucose (3 MBq/kg). After an average resting period of 91 ( $\pm 25.6$ ) minutes iodine containing contrast agent (Ultravist 370<sup>®</sup>, Bayer-Schering Healthcare, Berlin, Germany) was mechanically administered into an antibrachial cannula using a power injector (Accutron CT-D, Medtron AG, Saarbruecken, Germany), and the single spiral CT acquisition was started with a fixed delay of 70 s. The PET acquisitions were run subsequently in 7–8 steps, depending on patient length and exam volumes. For this study full field of view (500 × 500 mm) images were reconstructed using a smooth filtered back projection kernel (B31), slice thickness 5.0 mm and increment 5.0 mm. The resulting voxel size was 0.98 × 0.98 × 5.00 mm.

**Conventional calculation of effective dose.** Tube current time product, CTDIvol and DLP were recorded for each examination from the PET-CT scan protocol as provided by the scanner. Details about their definition and calculation are reported elsewhere in literature<sup>6</sup>. The main drawback of these monitoring techniques is that they are unable to provide information about the biological impact of radiation exposure and should only be taken as an index of radiation output by the CT system for comparative purposes<sup>9,17</sup>. The biologically relevant effective dose ( $ED_{DLP}$ ) was calculated for each examination by multiplication of DLP and the region-specific conversion factor. For this study  $k_{body}$  (0.015 mSv/mGy·cm) was used as recommended by the American Association of Physicists in Medicine<sup>6</sup>. Dose exposition related to 18F-fluorodeoxyglucose (FDG)-PET were not considered for ED calculation.

**Phantom based calculation of effective dose.** Academic reference ED was calculated using a dedicated CT dosimetry software tool provided by the National Cancer Institute (NCI-CT)<sup>7</sup>, which combines reference phantoms provided by the International Commission on Radiological Protection (ICRP) and MC simulations of a reference CT scanner (Somatom Sensation 16, Siemens Healthcare GmbH, Forchheim, Germany). Individual examination parameters, gender, age, height and body weight were used as input for this mathematical phantom based calculation ( $ED_{NCI}$ ). Dedicated descriptions about computational methods of this software are available in the literature<sup>7</sup>.

**Organ segmentation.** All radiosensitive organs or tissues including all remainders, which are mentioned in ICRP report 103 were segmented using a dedicated software package (ITK-SNAP 1.8, Penn Image Computing and Science Laboratory, Philadelphia, USA). Semi-automatic threshold segmentation with manual corrections was used for the lungs, cortical bone, bone marrow, liver, spleen, brain, heart, muscle and skin. All other organs or tissues were segmented manually in a slice per slice fashion. Therefore, missing organs due to aplasia or resection, organ hypo- or hypertrophy, skeletal deformations and metal implants were considered. For hollow organs, only voxels contributing to the wall were considered to contain radiosensitive tissues. Segmentation of lymphatic tissues was restricted to visible lymphatic nodes (Fig. 2). All segmentations were performed by a specially trained



**Figure 3.** Flow chart illustrating radiation dose terms in computed tomography (CT): Air kerma, Monte Carlo simulations (MC) and organ segmentations (OS) are used for absorbed organ dose calculation. Multiplication of absorbed organ dose with radiation weighting factors ( $W_R$ ) results in equivalent organ dose. For calculation of effective organ dose ( $ED_{ORGAN}$ ) tissue weighting factors ( $W_T$ ) are required. Effective whole-body dose ( $ED_{MC}$ ) is the sum ( $\Sigma$ ) of each  $ED_{ORGAN}$ . Data from BEIR VII report was used to estimate Lifetime Attributable Risk ( $LAR_{MC}$ ) of cancer mortality and to calculate its relation to the baseline of lifetime attributable cancer risk as Excess Relative Risk (ERR).

radiology resident (4 years experience) and reviewed from an experienced board-certified radiologist (9 years experience).

**Monte Carlo based calculation of effective dose.** Extensive mathematical models in simulation techniques can be utilized to calculate dose distribution for each voxel of CT scan volumes using the attenuation values and geometry from DICOM datasets as input<sup>18,19</sup>. All MC dose simulations were carried out using the software package ImpactMC (VAMP GmbH, Erlangen, Germany). Software details and information concerning the Monte Carlo calculation algorithms are reported elsewhere<sup>18,20</sup>. Multiplication of the resulting relative dose values per voxel with air kerma provides the absorbed dose for each voxel. The air kerma is a scanner specific value, which describes the kinetic energy transferred in air dependent on geometry and tube settings. It can be considered as measurement of x-ray beam intensity without object, which was 18.3 mGy for this study. The averaged absorbed dose over an organ volume, defined from segmentations, provides the absorbed organ dose. Equivalent organ dose was calculated by multiplication with the radiation weighting factor for photons ( $W_R = 1$ ) and used for subsequent effective organ dose calculations ( $ED_{Organ}$ ) by multiplication with the dedicated tissue weighting factor ( $W_T$ ) as recommended in ICRP report 103<sup>21</sup>. The sum of all effective organ doses provides  $ED_{MC}$  for each individual (Fig. 3). The relative contribution of the respective  $ED_{Organ}$  to the  $ED_{MC}$  was calculated following Eq. 1:

$$C_{Organ} = ED_{Organ}/ED_{MC} \quad (1)$$

Individual conversion factors ( $k_{MC}$ ) were calculated using Eq. 2 to illustrate the differences compared to the conventional calculation method using DLP and  $k_{body}$

$$k_{MC} = ED_{MC}/DLP \quad (2)$$

**Radiation risk assessment.** Lifetime Attributable Risk (LAR) is defined as risk of disease of an exposed cohort in comparison to a non-exposed cohort. Calculations of LAR for cancer mortality were based on report VII about Biologic Effects of Ionizing Radiation (BEIR VII). The BEIR VII report refers to an individual radiation dose exposure of 100 mGy. Assuming a linear risk distribution between decennium age intervals  $LAR_{MC}$  was derived from  $ED_{MC}$  by linear interpolation between the younger ( $N_y$ ) and older ( $N_o$ ) cohort as shown in equation 3 using patient age ( $A_p$ ) and the age of the younger cohort ( $A_y$ ) as input values<sup>22</sup>.

Equation 3: Calculation of individual LAR

$$LAR_{MC} = \left( N_y - \left( N_y - N_o \right) * \frac{A_p - A_y}{10 \text{ years}} \right) * \frac{ED_{Organ}}{100 \text{ mGy}}$$

The Excess Relative Risk ( $ERR_{MC}$ ), as a measurement of the exceeding risk of an exposed person compared to a non-exposed person, was calculated using the solid cancer mortality in the United States as baseline (female: 17500/100000; male: 22100/100000) using equation 4<sup>23</sup>.

Equation 4: Calculation of individual ERR

BMI [kg/m <sup>2</sup> ]	<20	20–25	>25	>30	total		
Age [years]							
<40		1♀	1♀	1♂		n = 3	
40–55		1♀	1♀	4♂	1♂	n = 7	
55–70			1♀	2♂	3♂	1♂	n = 7
>70			1♀		1♂	3♂	n = 5
	total	n = 2	n = 11	n = 5	n = 4	n = 22	

**Table 1.** Demographic characteristics and body mass index (BMI) of the patient collective.

$$ERR_{MC} = LAR_{MC}/LAR_{baseline}$$

**Pairwise patient comparison.** Because of the rather small patient collective in this study, mainly due to the extensive effort needed for segmentation of all radiosensitive tissues, pairwise patient comparisons were selected to highlight the influence of individual patient characteristics on the radiation dose parameters and radiation risk estimation. Matching patient pairs, each with two comparable values and one variable parameter, were found for the parameters age, sex and BMI.

**Statistical analysis.** All statistical analyses were performed using the software package SPSS Statistics Version 21 (IBM, Somers, NY, USA). Normal distribution of the data was tested by Kolmogorov-Smirnov and Shapiro-Wilk test. Normally distributed data is presented as mean  $\pm$  standard deviation. Median and range are provided if no normal distribution was assumed. Illustration is provided as Bland-Altman plots. Spearman's rank order test was used to test for correlations between tube current, BMI, ED<sub>DLP</sub> and ED<sub>MC</sub>. The significance level was defined as  $p < 0.05$ .


## Results

**Demographics of the study collective.** Five out of 22 patients (23%) were female and 17 male (77%). The mean age was  $57.3 \pm 14.3$  years and the mean BMI was  $26.0 \pm 5.9$  kg/m<sup>2</sup>. Three patients (13.6%) were younger than 40 years. The female patient group was younger ( $53.6 \pm 17.6$  years) compared to the male patient group ( $58.4 \pm 13.6$  years). Female patients had a lower mean BMI ( $21.2 \pm 2.5$  kg/m<sup>2</sup>) compared to male patients ( $27.4 \pm 5.88$  kg/m<sup>2</sup>). From the male subgroup 9 patients (52.9%) suffered from overweight (BMI > 25), and three patients (17.6%) had severe overweight (BMI > 30). One female and one male patient were considered as underweight (BMI < 19). No overweight patient was found in the female subgroup. Detailed patient characteristics are shown in Table 1.

**Organ specific radiation dose exposure.** Mean equivalent organ dose was  $13.0 \pm 3.5$  mGy. Highest equivalent organ dose values were found in high attenuating structures such as the cortical bone and the thyroid gland. Lowest values were found in profound organs like the extra-thoracic (ET) respiratory region and the uterus. Many superficial organs like muscles ( $11.5 \pm 2.0$  mGy), breast tissue ( $10.9 \pm 0.8$  mGy) and salivary glands ( $14.3 \pm 2.8$  mGy) also had rather low equivalent organ dose values. Despite its profound position well perfused kidneys had very high equivalent organ dose values ( $17.0 \pm 2.1$  mGy).

Effective organ dose was mainly influenced by  $W_T$ , nicely demonstrated by the thyroid gland. It has the second highest mean equivalent organ dose ( $21.2 \pm 5.4$  mGy), but is only ranked 7<sup>th</sup> highest effective organ dose (8% of total organ dose distribution) because of the rather low  $W_T$  (0.04). In contrast, the lungs ranked only 7<sup>th</sup> in equivalent organ dose ( $13.4 \pm 1.9$  mGy), but received highest effective organ dose levels in female and male patients (12% and 14% of the total ED<sub>MC</sub>) due to high  $W_T$  (0.12). Colon, lungs and stomach contributed to more than 50% of the total ED<sub>MC</sub> in male patients and to 48% in female patients (Fig. 4). Differences between  $W_T$  and the relative contribution of the effective organ dose to whole body ED<sub>MC</sub> ( $C_{Organ}$ ) reflect the influence of individual radiation dose distribution on each organ dose. Highest positive differences between  $W_T$  and  $C_{Organ}$  were found for the bone surface (♀: +102.1%; ♂: +134.8%), the thyroid gland (♀: +89.1%; ♂: +78.1%) and the kidneys (♀: +49.4%; ♂: +47.1%). The male gonads also had substantially higher  $C_{Organ}$  than expected from its rather low  $W_T$  (+38.2%), but the female gonads had the highest negative difference of all organs (−21.8%). Other organs with high negative differences were the adrenal glands (♀: −18.3%; ♂: −11.8%). Detailed organ dose information is shown in Table 2 and organ-based LAR of cancer mortality is provided for all organs listed in BEIR VII. Considering the similar effective organ doses of the lung ( $1.48 \pm 0.15$  mSv) and the breast ( $1.30 \pm 0.09$  mSv) the LAR for pulmonary malignant disease ( $13.25 \pm 4.24/100.000$ ) was remarkably higher compared to the LAR for breast cancer mortality ( $2.46 \pm 1.62/100.000$ ).

**Effective dose and individual radiation risk assessment.** ED<sub>DLP</sub> ( $13.2 \pm 4.52$  mSv) was higher than ED<sub>MC</sub> ( $11.6 \pm 1.47$  mSv) and ED<sub>NCl</sub> ( $9.8 \pm 2.1$  mSv). Particularly high differences between ED<sub>MC</sub> and ED<sub>DLP</sub> were found for patients with relatively high or low radiation dose exposure. Mean difference between both methods was −1.7 mSv (Fig. 5a). The same tendency was found for the comparison of ED<sub>NCl</sub> and ED<sub>DLP</sub> but with higher mean negative differences −3.4 mSv (Fig. 5b). A comparison between the three calculation methods is illustrated as boxplot (Fig. 6). The range of radiation dose was substantially smaller in both advanced methods (ED<sub>MC</sub>: 5.6 mSv, ED<sub>NCl</sub>: 10.2 mSv) compared to the conventional technique (ED<sub>DLP</sub>: 19.3 mSv). Effective mAs and DLP



**Figure 4.** Effective organ dose distribution for male (a) and female (b) patient subgroup.

linearly increased with higher BMI in Spearman's rank order test ( $r_s = 0.961$  and  $0.949$ ). This effect should be mainly due to the anatomy-based tube current modulation algorithm. Therefore, also BMI and  $ED_{DLP}$  had a high correlation coefficient ( $r_s = 0.949$ ). The correlation between  $ED_{MC}$  and BMI ( $r_s = 0.644$ ) was less and differences between  $ED_{DLP}$  and the advanced techniques was especially high in over- and underweight patients. For example, the highest  $ED_{DLP}$  of 26.3 mSv was found in a 77-year-old man suffering from adiposity grade 3 (BMI  $40.0 \text{ kg/m}^2$ ) while  $ED_{NCI}$  (17.3 mSv) and  $ED_{MC}$  (13.9 mSv) were substantially lower (34% and 47% less). Lowest  $ED_{DLP}$  of 7.0 mSv was calculated for a 30-year-old underweight man (BMI  $16.8 \text{ kg/m}^2$ ), which was close to  $ED_{NCI}$  (7.1 mSv), but substantially lower than  $ED_{MC}$  (8.5 mSv, 21% higher). Consequently, the individually calculated conversion factors ( $k_{MC}$ ) have a range from 53% to 140% when referred to  $k_{Body}$  from literature. The mean  $k_{MC}$  ( $0.014 \pm 0.004 \text{ mSv/mGy cm}$ ) approximately reflects the established value ( $0.015 \text{ mSv/mGy cm}$ ), which therefore seems to be suitable for regular weight patients. However, only one fourth of the patients in this study ( $n = 6$ , 27.2%) had less than 10% difference between  $k_{MC}$  ( $0.0135\text{--}0.0165 \text{ mSv/mGy cm}$ ) and  $k_{Body}$  (mean BMI  $22.95 \pm 1.58$ , range  $20.7\text{--}25.0 \text{ kg/m}^2$ ).

The values of LAR were especially high in young female patients. The highest value ( $60/100.000$ ) was calculated for a 30-year-old, normal weight woman (BMI  $21.6 \text{ kg/m}^2$ ). In contrast, low LAR values were calculated for older, predominantly male patients. The lowest value ( $23/100.000$ ) was found for a 76-year-old, overweight man (BMI  $29.8 \text{ kg/m}^2$ ). Extent of  $ED_{MC}$ ,  $ED_{DLP}$  and LAR often differed considerably when compared between young and old or underweight and obese patients, while the interaction between these individual parameters was rather difficult to predict. Detailed results of radiation dose and risk calculations are provided in Table 3.

**Pairwise patient comparison.** Two male patients with matching constitution (BMI 24 vs.  $23 \text{ kg/m}^2$ ) but different age (36 versus 67 years) had comparable DLP (783 vs. 724  $\text{mGy} \cdot \text{cm}$ ,  $-7.5\%$ ),  $ED_{DLP}$  (11.8 vs. 10.9 mSv,  $-7.5\%$ ),  $ED_{NCI}$  (9.4 vs. 9.0 mSv,  $-4.3\%$ ) and  $ED_{MC}$  (10.9 vs. 10.0 mSv,  $-8.4\%$ ). Nevertheless, calculations for LAR of cancer mortality ( $41.3$  vs.  $27.1/100.000$ ;  $-34.4\%$ ) and ERR (0.19 vs. 0.12%,  $-36.8\%$ ) differed considerably. The

Organs	Equivalent organ dose [mGy]	$W_T$	Effective organ dose (female) [mSv]	Effective organ dose (male) [mSv]	$C_{ORGAN}$ (female)	$C_{ORGAN}$ (male)	LAR of cancer mortality [n/100000]
Red bone marrow	12.3 ( $\pm$ 2.3)	0.12	1.49 ( $\pm$ 0.24)	1.47 ( $\pm$ 0.28)	0.125	0.126	
Colon	11.2 ( $\pm$ 2.8)	0.12	1.28 ( $\pm$ 0.08)	1.36 ( $\pm$ 0.38)	0.108	0.116	4.69 ( $\pm$ 1.88)
Lung	13.4 ( $\pm$ 1.9)	0.12	1.48 ( $\pm$ 0.15)	1.64 ( $\pm$ 0.38)	0.125	0.14	13.25 ( $\pm$ 4.24)
Stomach	12.2 ( $\pm$ 1.5)	0.12	1.39 ( $\pm$ 0.06)	1.48 ( $\pm$ 0.23)	0.117	0.127	1.43 ( $\pm$ 0.47)
Breast	10.9 ( $\pm$ 0.8)	0.12	1.30 ( $\pm$ 0.09)		0.11		2.46 ( $\pm$ 1.62)
Gonads	14.6 ( $\pm$ 4.1)	0.08	0.74 ( $\pm$ 0.07)	1.29 ( $\pm$ 0.26)	0.063	0.111	1.94 ( $\pm$ 0.84)
Bladder	11.7 ( $\pm$ 2.0)	0.04	0.40 ( $\pm$ 0.05)	0.49 ( $\pm$ 0.06)	0.034	0.042	1.88 ( $\pm$ 0.47)
Liver	12.0 ( $\pm$ 1.2)	0.04	0.46 ( $\pm$ 0.04)	0.49 ( $\pm$ 0.08)	0.039	0.042	1.22 ( $\pm$ 0.41)
Esophagus	11.1 ( $\pm$ 1.4)	0.04	0.42 ( $\pm$ 0.05)	0.45 ( $\pm$ 0.01)	0.035	0.039	
Thyroid gland	21.2 ( $\pm$ 3.2)	0.04	0.90 ( $\pm$ 0.04)	0.83 ( $\pm$ 0.05)	0.076	0.071	
Skin	11.0 ( $\pm$ 2.1)	0.01	0.09 ( $\pm$ 0.00)	0.11 ( $\pm$ 0.03)	0.08	0.01	
Bone surface	26.6 ( $\pm$ 4.7)	0.01	0.24 ( $\pm$ 0.01)	0.27 ( $\pm$ 0.03)	0.02	0.023	
Salivary glands	14.3 ( $\pm$ 2.8)	0.01	0.12 ( $\pm$ 0.01)	0.15 ( $\pm$ 0.03)	0.01	0.013	
Brain	12.7 ( $\pm$ 3.3)	0.01	0.10 ( $\pm$ 0.00)	0.14 ( $\pm$ 0.03)	0.08	0.012	
Remainder tissues							
Spleen	12.4 ( $\pm$ 1.7)	0.0092	0.11 ( $\pm$ 0.01)	0.12 ( $\pm$ 0.02)	0.009	0.01	
Kidney	17.0 ( $\pm$ 2.1)	0.0092	0.16 ( $\pm$ 0.01)	0.15 ( $\pm$ 0.02)	0.014	0.013	
Heart	12.5 ( $\pm$ 1.5)	0.0092	0.12 ( $\pm$ 0.01)	0.12 ( $\pm$ 0.01)	0.01	0.01	
Pancreas	11.7 ( $\pm$ 1.2)	0.0092	0.11 ( $\pm$ 0.01)	0.11 ( $\pm$ 0.01)	0.009	0.009	
Oral mucosa	13.5 ( $\pm$ 3.1)	0.0092	0.12 ( $\pm$ 0.01)	0.13 ( $\pm$ 0.03)	0.009	0.011	
Lymph nodes	12.6 ( $\pm$ 2.2)	0.0092	0.12 ( $\pm$ 0.02)	0.12 ( $\pm$ 0.02)	0.009	0.01	
Muscle	11.5 ( $\pm$ 1.9)	0.0092	0.11 ( $\pm$ 0.01)	0.11 ( $\pm$ 0.02)	0.008	0.009	
Small intestine	13.2 ( $\pm$ 1.9)	0.0092	0.12 ( $\pm$ 0.00)	0.13 ( $\pm$ 0.02)	0.009	0.011	
Gall bladder	11.6 ( $\pm$ 1.3)	0.0092	0.11 ( $\pm$ 0.01)	0.11 ( $\pm$ 0.01)	0.008	0.009	
Adrenal gland	10.2 ( $\pm$ 1.3)	0.0092	0.09 ( $\pm$ 0.01)	0.10 ( $\pm$ 0.01)	0.008	0.008	
Prostate	11.4 ( $\pm$ 3.2)	0.0092		0.10 ( $\pm$ 0.03)		0.008	0.74 ( $\pm$ 0.25)
Uterus	9.9 ( $\pm$ 1.1)	0.0092	0.09 ( $\pm$ 0.01)		0.008		0.28 ( $\pm$ 0.09)
Extrathoracic respiratory (ET) region	8.7 ( $\pm$ 7.1)	0.0092	0.08 ( $\pm$ 0.06)	0.07 ( $\pm$ 0.07)	0.009	0.006	

**Table 2.** Illustration of equivalent organ dose, tissue weighting factors ( $w_T$ ), effective organ dose ( $ED_{ORGAN}$ ), the relative contribution of  $ED_{ORGAN}$  to whole-body effective dose ( $C_{ORGAN}$ ) and estimation of organ-specific Lifetime Attributable Risk (LAR) of cancer mortality based on Monte Carlo simulations and report VII about Biologic Effects of Ionizing Radiation (BEIR VII).


young age seems to be the decisive factor among all the considered factors, accounting for about 50% higher risk estimates (Fig. 7a).

Two male patients with matching age (76 and 77 years) but different BMI (29.7 vs. 40.0 kg/m<sup>2</sup>, +34.7%) were exposed to considerably different DLP (998 vs. 1751 mGy-cm, +75.4%) based on anatomic tube current modulation. Therefore,  $ED_{DLP}$  calculations provided very high values for the obese patient (15.0 vs. 26.3 mSv, +75.5%). Dose differences calculated with  $ED_{NCI}$  (10.5 vs. 17.3 mSv, +64.5%) were also considerably high, while  $ED_{MC}$  values were nearly comparable (11.9 vs. 13.8 mSv; +15.9%). Differences in  $LAR_{MC}$  (22.8 vs. 25.1/100,000; +9.6%) and ERR (0.10 vs 0.11%; +10.0%) were even less (Fig. 7b). BMI seems to have only a minor influence on effective dose and risk estimation, while conventional methods would have resulted in an overestimation of almost 100%.


Two patients with matching age (56 and 54 years) and BMI (21.5 vs 21.0 kg/m<sup>2</sup>) but different sex had similar DLP (634 vs. 630 mGy-cm; +0.63%). ED was the same using the conventional method in both patients ( $ED_{DLP}$  = 9.5 mSv) and almost the same with the NCI method ( $ED_{NCI}$  = 8.7 vs 9.0 mSv; -3.3%).  $ED_{MC}$  calculation was slightly higher for the female patient (12.3 vs. 10.3 mSv; +19.4%), but LAR (53.1 vs. 35.4/100,000; +50.2%) and ERR (0.3% vs. 0.16%; +87.5%) were substantially higher. Sex seems to have a dominant impact on the risk estimation. Moreover, the unfavorable combination of age and sex leads to the highest values in the entire study collective, despite average ED values (Fig. 7c).

## Discussion

Individual radiation dose assessment and risk calculation is feasible by image based Monte Carlo simulations and organ segmentations in an adult clinical routine collective that underwent full body exposure in a single spiral acquisition. This is in good agreement with the findings of Li *et al.* and Tian *et al.* who evaluated comparable techniques for radiation dose estimation in small pediatric collectives ( $n = 2$  and  $n = 42$ )<sup>16,24</sup>. A comparable approach for cancer risk estimation in adults based on anthropomorphic phantoms was described by Huda *et al.*<sup>11</sup>. In contrast to these prior studies, we provide a combination of individual radiation dose analysis, voxel-based organ



**Figure 5.** (a) Bland-Altman plot for the difference between conventional effective dose calculation ( $ED_{DLP}$ ) and calculation based on Monte Carlo simulations ( $ED_{MC}$ ): The difference between both methods increases with high and low values of mean ED. This implicates that in high and low mean ED the conventional  $ED_{DLP}$  over- and underestimates radiation dose exposure compared to  $ED_{MC}$ . (b) Bland-Altman plot for the difference between  $ED_{DLP}$  and calculation by the National Cancer Institute dosimetry system for CT ( $ED_{NCI}$ ): The difference between both methods increases especially with high values of mean ED. This suggests that in high mean ED the conventional  $ED_{DLP}$  overestimates radiation dose exposure compared to  $ED_{NCI}$  (red triangles indicate female patients).



**Figure 6.** Comparison of effective dose for  $ED_{DLP}$ ,  $ED_{NCI}$  and  $ED_{MC}$  illustrated as boxplot.

segmentation and cancer risk estimation in direct comparison to such phantom based estimation and the DLP method. The need for such an advanced dose monitoring method, due to several uncertainties with the conventional techniques, has been raised elsewhere in literature<sup>20,25</sup>.

In our study high equivalent organ doses were strongly related to radiodensity (e.g. bone surface and high contrast medium uptake in the kidneys, the thyroid gland and the extra-thoracic respiratory region), which seems to



age [y]	sex	weight [kg]	BMI	DLP [mGy · cm]	CTDIvol [mGy]	eff. mAs [mAs]	ED <sub>DLP</sub> [mSv]	ED <sub>NCI-CT</sub> [mSv]	ED <sub>MC</sub> [mSv]	ED <sub>NCI</sub> /ED <sub>DLP</sub> deviation [%]	ED <sub>MC</sub> /ED <sub>DLP</sub> deviation [%]	k <sub>MC</sub>	LAR <sub>MC</sub> <sup>*</sup>	ERR <sub>MC</sub> [%]
30	W	70	21.6	675	5.8	86	10.1	7.4	11.1	-26.7	9.9	0.016	60	0.34%
48	W	54	21.1	545	5.4	80	8.2	7.6	10.9	-7.3	32.9	0.020	52	0.30%
55	W	46	17.3	554	5.5	81	8.3	8.3	11.5	0.0	38.9	0.021	51	0.29%
56	W	62	21.5	634	6.3	93	9.5	8.7	12.3	-8.4	29.5	0.019	53	0.30%
79	W	65	24.5	656	6.5	96	9.8	8.6	12.7	-12.2	29.6	0.019	26	0.15%
30	M	51	16.8	464	4.6	68	7.0	7.1	8.5	1.4	21.4	0.018	33	0.15%
36	M	68	24.1	783	6.8	100	11.8	9.4	10.9	-20.3	-7.6	0.014	41	0.19%
44	M	80	25.0	841	7.3	107	12.6	9.2	11.9	-27.0	-5.6	0.014	44	0.20%
52	M	84	25.9	827	7.1	105	12.4	8.8	11.1	-29.0	-10.5	0.013	39	0.18%
53	M	77	24.3	841	7.3	107	12.6	9.6	10.9	-23.8	-13.5	0.013	38	0.17%
53	M	72	24.3	836	7.2	106	12.5	10.1	11.5	-19.2	-8.0	0.014	40	0.18%
54	M	67	20.7	630	6.4	92	9.5	9.0	10.3	-5.3	8.4	0.016	35	0.16%
57	M	125	37.3	1399	12.1	178	21.0	11.7	13.9	-44.3	-33.8	0.010	46	0.21%
58	M	84	25.9	875	7.6	111	13.1	9.3	8.3	-29.0	-36.6	0.001	27	0.12%
59	M	78	24.6	949	8.2	121	14.2	10.4	12.4	-26.8	-12.7	0.013	40	0.18%
61	M	90	29.4	1135	9.8	145	17.0	11.9	13.9	-30.0	-18.2	0.012	43	0.20%
67	M	67	23.0	724	6.3	92	10.9	9.0	10.0	-17.4	-8.3	0.014	27	0.12%
69	M	86	28.7	1003	8.65	128	15.1	10.4	12.1	-31.1	-19.8	0.012	31	0.14%
73	M	102	33.7	1135	9.79	145	17.0	11.1	12.5	-34.7	-26.5	0.011	28	0.12%
74	M	100	31.9	1130	9.75	144	17.0	11.1	12.1	-34.7	-28.8	0.011	26	0.12%
76	M	86	29.8	998	8.61	127	15.0	10.5	11.9	-30.0	-20.7	0.012	23	0.10%
77	M	105	40.0	1751	17.36	165	26.3	17.3	13.8	-34.2	-47.5	0.008	25	0.11%
57.3 (±14.3)	♀ = 22.7%	78.1 (±19.0)	26.0 (±5.9)	881.1 (±301.0)	7.9 (±2.8)	112.6 (±28.6)	13.2 (±4.5)	9.8 (±2.1)	11.6 (±1.5)	-22.3 (±12.0)	-5.8 (±23.6)	0.014 (±0.004)	37.6 (±10.6)	0.18 (±0.07)


**Table 3.** Individual patient and radiation exposure characteristics with illustration of dose length product (DLP), volume computed tomography dose index (CTDIvol), effective mAs (eff. mAs), effective dose based on conventional calculation method (ED<sub>DLP</sub>), Monte Carlo simulations (ED<sub>MC</sub>) and the dosimetry system for CT provided by the National Cancer Institute (ED<sub>NCI</sub>). ED<sub>NCI</sub>/ED<sub>DLP</sub> and ED<sub>MC</sub>/ED<sub>DLP</sub> deviations, conversions factors (k<sub>MC</sub>), Lifetime Attributable Risk (LAR<sub>MC</sub>) and Excess Relative Risk (ERR<sub>MC</sub>) are individually calculated. \*Lifetime attributable risk (LAR) for all cancer mortality/100.000 persons.

be a much stronger predictor for equivalent organ dose than anatomical organ position. This is in good agreement with the contrast media related increase of DNA double-strand break foci after radiation exposure reported in a prior study for CT<sup>26</sup>.

W<sub>T</sub> is the strongest predictor of effective organ dose. For example, the thyroid gland and the kidneys have the second and third highest equivalent organ dose (21.2 ± 3.2 mSv and 17.0 ± 2.1 mSv). However, due to low tissue weighting factors (W<sub>T</sub> = 0.04 and 0.0092) effective organ dose of the thyroid gland and the kidneys were only sixth and twelfth highest.

Our results confirm that individual patient characteristics have a considerable impact on radiation dose calculation, which is underrepresented by the conventional method. The calculated error in our adult collective (-48 to 39%) is comparable to the previously published study results for children (-63 to 28%)<sup>19</sup>. Individually calculated k<sub>MC</sub> from our study reveals that the routinely used k<sub>body</sub> from literature can be applied to larger clinical collectives, but are limited in their value for individual risk assessment<sup>6</sup>. The DLP-method slightly overestimates the effective dose in general, but it seems to be appropriate in regular weight male patients. However, especially in female and underweight patients, underestimation of the effective dose may be critical for risk perception in the clinical setting. Moreover, its overestimation in obese patients may lead to restrained use of high exposure parameters, and then to poor or insufficient image quality. Individual anatomic characteristics (e.g. missing organs due to aplasia or resection, organ hypo- or hypertrophy, skeletal deformations, metal implants) may lead to considerable changes of radiation dose distribution and consequently of individual risk. Even phantom based estimation methods, like ED<sub>NCI</sub> in this study, are unable to take these individual properties into account<sup>7</sup>. Bland-Altman analysis demonstrated that these phantom based estimates have the tendency to underestimate ED in general, while the effect of only moderate increase of ED in obese patients despite the very high energy exposure is confirmed.

The influence of personal risk profiles on cancer risk estimates are not yet represented in standard radiation dose reporting systems. It can further increase the error of perceived and true risk of radiation dose from CT examinations. The combination of individual dose distributions and risk assessment has been presented for a few other examinations in literature, such as absorptiometry and spine radiographs, but not for spiral CT examinations<sup>27</sup>.



**Figure 7.** Pairwise comparison of dose length product (DLP), effective dose (ED), Lifetime Attributable Risk (LAR) and Excess Relative Risk (ERR) in dependence of age (a), Body Mass Index (b) and sex (c).

Pairwise patient comparisons provide a comprehensive overview of the extent of error with regard to age, BMI and sex. Especially younger patients are prone to higher LAR and ERR since more active cell division and longer life expectancy after radiation exposure is presumed<sup>28</sup>. In our example the ERR of a patient in his mid-thirties was 1.6-fold the ERR of a patient in his mid-sixties and the ERR for a female patient in her mid-fifties was almost doubled compared to a matching male patient. The increasing tube current by anatomy-based modulation in obese patients seems to be of less importance to the patients' cancer risk. CTDI and ED<sub>DLP</sub> were 1.8-fold higher for a high-grade obese patient compared to an overweight patient with matching age and sex, while the ERR was only 10% higher. Therefore, future dose assessment strategies should not only focus on absolute dose values. Furthermore, reporting LAR or ERR seems to be much more appropriate in clinical routine and a more comprehensible value for the patient-physician interaction.

Some limitations have to be considered while interpreting this study. First, the study population consisted of a heterogeneous, small and retrospectively selected patient collective with an imbalanced ratio of female to male patients. The small number of patients is mainly due to the high computing power required for MC calculations and the work intense manual organ segmentation that we used for this study. We estimate that the increasing computing power and automated organ segmentations by the application of artificial intelligence could overcome this limitation in the near future<sup>29,30</sup>. Second, only full body dose exposure is reported in this study. This avoids indeterminate scattered radiation to radiosensitive structures and over-ranging effects, but limits the findings to this clinically rather rare indication. Further evaluations for limited examination volumes could become feasible with retrospective simulations from these data in larger collectives by future studies. Third, all examinations were conducted on the same scanner. The findings of this study can therefore not automatically be transferred to other CT systems<sup>5,24</sup>. Forth, all tissue weighting factors that are provided in literature so far are averaged for sex and age, which may probably limit their applicability for patient specific risk estimation. Fifth, the linear Non-threshold Dose-Response Model itself is discussed controversially among experts for diagnostic dose levels<sup>31,32</sup>. Sixth, LAR and ERR calculations in this study are only related to low dose radiation exposure. They illustrate the individual radiation dose related risk to develop cancer. Obviously, the overall individual cancer risk for a primary or even a secondary cancer and also the life expectancy is potentially much more influenced by age, genetic make-up, efficiency of DNA damage repair, therapy-related adverse effects and many other influencing factors.

The importance of patient specific dose surveillance is illustrated by this study.  $ED_{DLP}$  can be used for radiation dose assessments in larger collectives, but individual considerations require advanced techniques like  $ED_{MC}$ . Conventional methods tend to underestimate radiation dose in underweight and female patients. Therefore, these patients have to be evaluated with special care. The influence of young patient age and female gender on cancer risk estimates is very high. Thus, radiation dose assessment should not only provide whole body or organ dose measurements but also individual risk calculations, which could be included in future surveillance programs.

## Data availability

The datasets generated during and analyzed during this study are available from the corresponding author on reasonable request.

Received: 21 January 2019; Accepted: 14 May 2020;

Published online: 11 June 2020

## References

1. EC. COUNCIL DIRECTIVE 2013/59/EURATOM of 5 December 2013 laying down basic safety standards for protection against the dangers arising from exposure to ionising radiation, a. r. D.
2. Laurier, D. *et al.* The International Nuclear Workers Study (Inworks): A Collaborative Epidemiological Study to Improve Knowledge About Health Effects of Protracted Low-Dose Exposure. *Radiation protection dosimetry* <https://doi.org/10.1093/rpd/ncw314> (2016).
3. Huda, W. & Mettler, F. A. Volume CT dose index and dose-length product displayed during CT: what good are they? *Radiology* **258**, 236–242, <https://doi.org/10.1148/radiol.10100297> (2011).
4. Blackwell, C. R. & McCullough, E. C. A chamber and electrometer calibration factor as determined by each of the five AAPM accredited dosimetry calibration laboratories. *Medical physics* **19**, 207–208, <https://doi.org/10.1118/1.596880> (1992).
5. Hill, K. D. *et al.* Radiation Safety in Children With Congenital and Acquired Heart Disease: A Scientific Position Statement on Multimodality Dose Optimization From the Image Gently Alliance. *JACC. Cardiovascular imaging* **10**, 797–818, <https://doi.org/10.1016/j.jcmg.2017.04.003> (2017).
6. AAPM. The Measurement, reporting, and management of radiation dose in CT. *AAPM Report No. 96* (2008).
7. Lee, C., Kim, K. P., Bolch, W. E., Moroz, B. E. & Folio, L. NCICT: a computational solution to estimate organ doses for pediatric and adult patients undergoing CT scans. *Journal of radiological protection: official journal of the Society for Radiological Protection* **35**, 891–909, <https://doi.org/10.1088/0952-4746/35/4/891> (2015).
8. Martin, C. J. Effective dose: how should it be applied to medical exposures? *The British journal of radiology* **80**, 639–647, <https://doi.org/10.1259/bjr/25922439> (2007).
9. McCollough, C. H., Christner, J. A. & Kofler, J. M. How effective is effective dose as a predictor of radiation risk? *AJR. American journal of roentgenology* **194**, 890–896, <https://doi.org/10.2214/AJR.09.4179> (2010).
10. Romanyukha, A., Folio, L., Lamart, S., Simon, S. L. & Lee, C. Body Size-Specific Effective Dose Conversion Coefficients for Ct Scans. *Radiation protection dosimetry* **172**, 428–437, <https://doi.org/10.1093/rpd/ncv511> (2016).
11. Huda, W. & He, W. Estimating cancer risks to adults undergoing body CT examinations. *Radiation protection dosimetry* **150**, 168–179, <https://doi.org/10.1093/rpd/ncr376> (2012).
12. Li, X. *et al.* Patient-specific dose estimation for pediatric chest CT. *Medical physics* **35**, 5821–5828, <https://doi.org/10.1118/1.3026593> (2008).
13. Kost, S. D. *et al.* Patient-specific dose calculations for pediatric CT of the chest, abdomen and pelvis. *Pediatric radiology* **45**, 1771–1780, <https://doi.org/10.1007/s00247-015-3400-2> (2015).
14. In Health Effects of Exposure to Low Levels of Ionizing Radiations: Time for Reassessment? (1998).
15. Kyriakou, Y., Kachelriess, M., Knaup, M., Krause, J. U. & Kalender, W. A. Impact of the z-flying focal spot on resolution and artifact behavior for a 64-slice spiral CT scanner. *European radiology* **16**, 1206–1215, <https://doi.org/10.1007/s00330-005-0118-9> (2006).
16. Li, X. *et al.* Patient-specific radiation dose and cancer risk estimation in CT: part II. Application to patients. *Medical physics* **38**, 408–419, <https://doi.org/10.1118/1.3515864> (2011).
17. McCollough, C. H. *et al.* CT dose index and patient dose: they are not the same thing. *Radiology* **259**, 311–316, <https://doi.org/10.1148/radiol.11101800> (2011).
18. Deak, P., van Straten, M., Shrimpton, P. C., Zankl, M. & Kalender, W. A. Validation of a Monte Carlo tool for patient-specific dose simulations in multi-slice computed tomography. *European radiology* **18**, 759–772, <https://doi.org/10.1007/s00330-007-0815-7> (2008).
19. DeMarco, J. J. *et al.* A Monte Carlo based method to estimate radiation dose from multidetector CT (MDCT): cylindrical and anthropomorphic phantoms. *Physics in medicine and biology* **50**, 3989–4004, <https://doi.org/10.1088/0031-9155/50/17/005> (2005).
20. Jarry, G., DeMarco, J. J., Beifuss, U., Cagnon, C. H. & McNitt-Gray, M. F. A Monte Carlo-based method to estimate radiation dose from spiral CT: from phantom testing to patient-specific models. *Physics in medicine and biology* **48**, 2645–2663 (2003).
21. The 2007 Recommendations of the International Commission on Radiological Protection. ICRP publication 103. *Annals of the ICRP* **37**, 1–332, <https://doi.org/10.1016/j.icrp.2007.10.003> (2007).
22. Rampinelli, C. *et al.* Exposure to low dose computed tomography for lung cancer screening and risk of cancer: secondary analysis of trial data and risk-benefit analysis. *Bmj* **356**, j347, <https://doi.org/10.1136/bmj.j347> (2017).
23. Lee, W. C. Excess relative risk as an effect measure in case-control studies of rare diseases. *PLoS one* **10**, e0121141, <https://doi.org/10.1371/journal.pone.0121141> (2014).
24. Tian, X. *et al.* Pediatric chest and abdominopelvic CT: organ dose estimation based on 42 patient models. *Radiology* **270**, 535–547, <https://doi.org/10.1148/radiol.13122617> (2014).
25. Jansen, J. T. & Shrimpton, P. C. Development of Monte Carlo simulations to provide scanner-specific organ dose coefficients for contemporary CT. *Physics in medicine and biology* **61**, 5356–5377, <https://doi.org/10.1088/0031-9155/61/14/5356> (2016).
26. Grudzenski, S., Kuefner, M. A., Heckmann, M. B., Uder, M. & Lobrich, M. Contrast medium-enhanced radiation damage caused by CT examinations. *Radiology* **253**, 706–714, <https://doi.org/10.1148/radiol.2533090468> (2009).
27. Law, M. *et al.* Cumulative Effective Dose and Cancer Risk of Pediatric Population in Repetitive Whole-Body Scan Using Dual-Energy X-Ray Absorptiometry. *Journal of clinical densitometry: the official journal of the International Society for Clinical Densitometry*, <https://doi.org/10.1016/j.jocd.2017.09.005> (2017).
28. Kalra, M. K., Sodikson, A. D. & Mayo-Smith, W. W. CT Radiation: Key Concepts for Gentle and Wise Use. *Radiographics: a review publication of the Radiological Society of North America, Inc* **35**, 1706–1721, <https://doi.org/10.1148/rg.2015150118> (2015).
29. McBee, M. P. *et al.* Deep Learning in Radiology. *Academic radiology*, <https://doi.org/10.1016/j.acra.2018.02.018> (2018).
30. Lee, H. *et al.* Pixel-Level Deep Segmentation: Artificial Intelligence Quantifies Muscle on Computed Tomography for Body Morphometric Analysis. *Journal of digital imaging* **30**, 487–498, <https://doi.org/10.1007/s10278-017-9988-z> (2017).
31. Shore, R. *et al.* Implications of recent epidemiologic studies for the linear nonthreshold model and radiation protection. *Journal of radiological protection: official journal of the Society for Radiological Protection*, <https://doi.org/10.1088/1361-6498/aad348> (2018).
32. Kase, K. R. Radiation protection principles of NCRP. *Health physics* **87**, 251–257 (2004).

### Author contributions

Contributed to the writing of the manuscript: M.K., M.M., T.L. and W.W. Study design, measurements and statistical analysis: M.K., M.M., W.W., M.Br., M.W., T.L., W.N., B.S., D.S., M.Be. and M.U. All authors reviewed the manuscript.

### Competing interests

M.K., M.M., W.W. and M.U. are members of the Siemens Speaker's Bureau. B.S. is an employee of Siemens Healthineers GmbH. M.W., T.L., M.Br., W.N., D.S. and M.Be. declare no competing financial interests. All authors declare no competing non-financial interests.

### Additional information

**Correspondence** and requests for materials should be addressed to M.K.

**Reprints and permissions information** is available at [www.nature.com/reprints](http://www.nature.com/reprints).

**Publisher's note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.



**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2020